Investigating how B cells manage harmful genetic elements to protect their DNA
RNA Decay of LINE-1 Retrotransposons as a New Mechanism to Maintain B Cell Genome Integrity
This study is looking at how a type of immune cell called B cells keeps their DNA safe from certain genetic elements that can cause problems, and it’s for anyone interested in understanding how our bodies protect themselves from diseases.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10902832 on NIH RePORTER |
What this research studies
This research focuses on understanding how B cells, a type of immune cell, maintain the integrity of their DNA by managing the activity of Long INterspersed Element-1 (LINE-1) retrotransposons. These genetic elements can disrupt normal gene function and contribute to diseases. The study will explore the role of an RNA processing complex in degrading LINE-1 RNA, which may help prevent potential damage to the genome. By using laboratory techniques, the research aims to uncover the mechanisms that B cells use to control these harmful elements.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with autoimmune conditions or B cell-related cancers.
Not a fit: Patients without B cell-related conditions or those not affected by genome instability may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing genome instability in B cells, which may improve treatments for autoimmune diseases and cancers.
How similar studies have performed: Other research has shown promising results in understanding the regulation of retrotransposons, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Lauring, Max Chen — Columbia University Health Sciences
- Study coordinator: Lauring, Max Chen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.